The "Bank of Beijing Cup China • Beijing Innovation and Entrepreneurship Competition Final" was held in Changyang Art Museum, Fangshan District, Beijing on August 29, 2019. There are more than 1000 entries in six major industries. After fierce competition, 67 high-quality projects emerged to reach the peak of the final. These are top project products in various industries in Beijing. Beijing Dongfang Baitai [Exendin-4 Fc antibody fusion protein (JY09) project] broke through the tight encirclement and won the second prize in 67 projects selected at all levels in Beijing.

The final of Beijing competition area gathered six top products in the industry from early May to the end of August. There are a wide range of upgraded products, ranging from national products to individual products. The event greatly encouraged the enthusiasm of innovative talents from all walks of life, helped the national development, helped people improve their quality of life, and provided more perfect services for all walks of life. The award-winning project of Beijing Dongfang Baitai Biotechnology Co., Ltd. (hereinafter referred to as Dongfang Baitai) is the Exendin-4 Fc antibody fusion protein (JY09) project. It can be seen that JY09 project is highly valued in the eyes of experts, judges and teachers. At the same time, people are also in need of such conscientious enterprises that can take patients into consideration and drug products that can reassure patients.

The reason why JY09 is so honored. Because it is one of the antibody drugs developed by Dongfang Baitai. It can treat type II diabetes for a long time. JY09 can be injected for 7-14 days without re injection, which reduces the pain of patients. In 7-14 days, if the patient forgets to use the drug repeatedly, there will be no risk of hypoglycemia, ensuring the patient's life safety.

And JY09 has the effect of repairing islets and promoting insulin secretion. It has obtained the "triple" project of the national major new drug discovery project, the "priority review" project recommended by the National Health and Family Planning Commission and the Chinese patent authorization. International PCT patents have been granted by the United States, Japan, South Korea, Europe, Eurasia and other countries. Brazil and India have entered the trial stage. At present, it has obtained the clinical approval document approved by the State Food and Drug Administration of China, and is conducting clinical research.

Beijing Dongfang Baitai was founded in 2011. It has been nearly 10 years since then. Sixteen research projects are being carried out in an orderly manner. Dongfang Baitai is a high-tech enterprise engaged in innovative antibody R&D and production. It has carried out nearly 20 R&D pipeline layouts in cancer, diabetes, autoimmune diseases, etc. The company has set up a high-level professional antibody research and development team of more than 100 people, with more than half of them having doctors and masters. Many doctors have overseas study or technical management experience. They have provided a solid R&D and production guarantee for Dongfang Baitai.

The high-level R&D team of Dongfang Baitai has undertaken a number of national and Beijing key research projects. The company has established the first batch of antibody engineering laboratories in Beijing, Beijing International Science and Technology Cooperation Base, as well as a number of key projects of the 11th and 12th Five Year Plan, such as the national "major new drug development" ministerial special projects and the "863" plan.

Dongfang Baitai takes promoting human health as its own responsibility and improving the quality of life as its goal. Taking "quality and innovation" as the eternal pursuit of the enterprise, we will research and explore in a scientific, professional and rigorous manner to help mankind overcome diseases and achieve health dreams. We will forge ahead on the road of drug research and development.